09:26 AM EST - Biovaxys Technology Corp : Announces that it has further extended its research collaboration with The Ohio State University for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research. This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021. Biovaxys Technology Corp
shares C.BIOV are trading up $0.02 at $0.03.
